本帖最后由 老马 于 2013-3-13 13:43 编辑
4 G- W2 ^, n3 H4 N2 U" t6 O8 C( e1 e h' s
健择（吉西他滨）+顺铂+阿瓦斯汀
5 d4 S5 ^ z) R" n; `( r1 b Gemzar +Cisplatin + Avastin, x; w+ U/ A* s1 O+ [
http://annonc.oxfordjournals.org/content/21/9/1804.full
# P$ }% K( j7 d- S- KOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
% m; N4 _$ ^7 u% Z! S |2 hPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
1 k) L6 j3 @" oResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; d- Y$ P4 I* E- c% J
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 636)
/ O v/ C, C2 X6 ^0 I4 Y* \华为网盘附件：
6 c" B( y" {; e V5 H/ D# Q( \( f$ k【华为网盘】ava.JPG' N: U9 u* k% C; G* d, S. d
|
显身卡
